The ex vivo effects of procarbazine and methylhydrazine on some rat amine oxidase activities

  • A. Holt
  • B. A. Callingham
Conference paper
Part of the Journal of Neural Transmission book series (NEURAL SUPPL, volume 41)


Monoamine oxidase (MAO) and semicarbazide-sensitive amine oxidase (SSAO) activities were examined in homogenates of various rat tissues following i.p. administration of procarbazine or methylhydrazine. Both compounds inhibited SSAO in a dose-dependent manner in all tissues examined, with methylhydrazine the more potent agent in this respect. Little inhibition of MAO could be detected in most cases. However, hepatic MAO-B activity was potentiated significantly in rats receiving methylhydrazine and both drugs caused a dose-dependent potentiation of MAO-A in homogenates of brown adipose tissue. The potential use of these compounds in vivo as selective SSAO inhibitors is discussed.


Monoamine Oxidase Brown Adipose Tissue Amine Oxidase Acad Child Adolesc Psychiatry Interscapular Brown Adipose Tissue 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Bonadonna G, Monfardini S, Oldini C (1969) Comparative effects of vinblastine and procarbazine in advanced Hodgkin’s disease. Eur J Cancer 5: 393–402.PubMedGoogle Scholar
  2. Coomes MW, Prough RA (1983) The mitochondrial metabolism of 1,2-disubstituted hydrazines, procarbazine and 1,2-dimethylhydrazine. Drug Metab Dispos 11: 550–555.PubMedGoogle Scholar
  3. De Vita VT, Hahn MA, Oliverio VT (1965) Monoamine oxidase inhibition by a new carcinostatic agent, N-isopropyl-α-(2-methylhydrazino)-p-toluamide (MIH). Proc Soc Exp Biol Med 120: 561–565.PubMedGoogle Scholar
  4. Holt A, Sharman DF, Callingham BA, Kettler R (1992a) Characteristics of procarbazine as an inhibitor in vitro of rat semicarbazide-sensitive amine oxidase. J Pharm Pharmacol 44: 487–493.PubMedCrossRefGoogle Scholar
  5. Holt A, Sharman DF, Callingham BA (1992b) Effects in vitro of procarbazine metabolites on some amine oxidase activities in the rat. J Pharm Pharmacol 44: 494–499.PubMedCrossRefGoogle Scholar
  6. Koenig J-J, Moureau F, Vercauteren D, Durant F, Ducrey F, Jarreau F-X (1992) Befloxatone, a spontaneously reversible MAO-A inhibitor: modélisation at molecular level. Clin Neuropharmacol 15 [Suppl] 1: 424B.CrossRefGoogle Scholar
  7. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193: 265–275.PubMedGoogle Scholar
  8. Lyles GA, Callingham BA (1982) In vitro and in vivo inhibition by benserazide of clorgyline-resistant amine oxidases in rat cardiovascular tissues. Biochem Pharmacol 31: 1417–1424.PubMedCrossRefGoogle Scholar
  9. Pffeferbaum B, Pack R, van Eys J (1989) Monoamine oxidase inhibitor toxicity. J Am Acad Child Adolesc Psychiatry 28: 954–955.CrossRefGoogle Scholar
  10. Strolin Benedetti M, Dostert P (1992) Monoamine oxidase: from physiology and pathophysiology to the design and clinical application of reversible inhibitors. Adv Drug Res 23: 65–125.Google Scholar
  11. van Eys J, Cangir A, Coody D, Smith B (1985) MOPP regimen as primary chemotherapy for brain tumors in infants. J Neurooncol 3: 237–243.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • A. Holt
    • 1
  • B. A. Callingham
    • 1
  1. 1.Department of PharmacologyUniversity of CambridgeCambridgeUK

Personalised recommendations